PTK2 and cancer: Inhibitors specifically targeting the p53 or Mdm2 binding site on the FERM domain of nuclear FAK are also promising in treating cancers without deleterious mutations of p53 as indicated by an inhibitor of the putative p53 binding site on FAK FERM exhibiting tumor-suppressive effects by dampening FAK-induced p53 degradation [218].